Use of the insulin pump in treat cystic fibrosis related diabetes  by Hardin, Dana S. et al.
(2009) 174–178
www.elsevier.com/locate/jcfJournal of Cystic Fibrosis 8Use of the insulin pump in treat cystic fibrosis related diabetes☆
Dana S. Hardin a,b,⁎, Julie Rice a,b, Mark Rice a,b, Randall Rosenblatt c
a Nationwide Children's Hospital Research Institute, United States
b The Ohio State University, United States
c University of Texas Southwestern Medical School, United States
Received 16 June 2008; received in revised form 21 August 2008; accepted 7 December 2008
Available online 21 January 2009Abstract
Objectives: This study was conducted to determine efficacy and tolerability of the continued subcutaneous insulin infusion (CSII) via an insulin
pump for treatment of Cystic Fibrosis Related Diabetes (CFRD). We also tested the hypothesis that CSII would improve body weight, blood sugar
control, lean body mass, whole body protein turnover, hepatic glucose production (HGP).
Methods: We recruited 9 CF patients with established diabetes and placed them on insulin pump therapy for six months. Each subject kept daily
blood sugar records before and during pump use. Prior to the pump placement and at the end of six months, each patient underwent the following
measurements: 1) whole body protein turnover using the stable isotope [1-13C] leucine; 2) DEXA scan for measurement of lean body mass;
3) anthropometric measurements; 4) Hemoglobin A1c. Patient data was compared to baseline data and the mean change from baseline was analyzed.
Results: There was significant improvement in both fasting and post-prandial blood glucose levels, body weight, HbA1C, and lean mass. Protein
catabolism as measured by leucine rate of appearance was significantly lower, as was hepatic glucose production. No patient developed
hypoglycemia during the study.
Conclusions: This study demonstrates that CSII is safe and effective for treatment of CFRD and that metabolic benefits are also present.
© 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis related diabetes; Insulin pump; Hepatic glucose production1. Introduction
Nearly 75% of patients with cystic fibrosis (CF) have
impaired glucose tolerance and 15% have frank diabetes, called
CF related diabetes or CFRD [1]. CFRD is caused by a com-
bination of insulin deficiency [2], peripheral and hepatic insulin
resistance [3,4] and defective substrate metabolism, including
high rates of hepatic glucose production (HGP) and protein
catabolism [5]. The 1998 CF Foundation Consensus conference
of diabetes recommended that all patients who have CFRD withAbbreviations: CF, Cystic Fibrosis; FBG, Fasting Blood Glucose; PP, 2 hour
post-prandial blood glucose; HGP, Hepatic Glucose Production; CFRD, CF
Related Diabetes.
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doi:10.1016/j.jcf.2008.12.001fasting hyperglycemia routinely receive insulin treatment. The
most effective insulin regimen in this population is multiple
insulin injections with meals and snacks [6]. Effective dietary
management of CF requires large caloric intake and many CF
patients eat 4–8 meals and large snacks per day [7]. The
carbohydrate content of these meals and snacks necessitates the
need for insulin with all of them. Understandably, many CF
patients are reluctant to take insulin injections with such fre-
quency. Continuous subcutaneous insulin infusion (CSII) by the
insulin pump has been accepted for treatment of patients with
type 1 and type 2 diabetes [4,8,9], and has been proven to be
more effective for improved blood glucose control than
subcutaneous injections [10]. Although the insulin pump has
not been routinely utilized for CFRD, one case report from three
patients suggests clinical benefits [11].
Potential advantages for the CF patient include the ability to
give a “bolus” dose of insulin with every meal and snack,
without needing to give a shot. A further advantage of the pumpropean Cystic Fibrosis Society.
175D.S. Hardin et al. / Journal of Cystic Fibrosis 8 (2008) 174–178is that the basal insulin dose can be easily adjusted. The ability
to provide adjustable basal insulin may be of particular benefit
to the CF patient as multiple studies have demonstrated negative
physiologic affects from insulinopenia [12,13]. Thus the first
purpose of our study was to determine the efficacy and safety of
pump use for patients with CFRD.
Previous studies in CF have demonstrated increased protein
catabolism [14,15] and studies by our group [16] and others
[17,18] have described resistance to insulin's anti-catabolic
effect on protein breakdown (i.e. they need more insulin to
suppress protein catabolism than a non-CF person, yet they are
insulin deficient) [2]. Insulin is a key anabolic hormone and
plays an important role in the regulation of protein metabolism
by causing a dose-dependent restraint of protein breakdown
[19]. Thus a second purpose of our study was to evaluate the
effectiveness of pump therapy on improving protein catabolism.
The pre-diabetes state of CF is associated with elevation of
post-prandial glucose levels [1]. We believe high post-prandial
glucose levels are in part secondary to high hepatic glucose
production (HGP) in CF patients [5,20]. In the fed state, the
liver normally ceases producing glucose and stores glucose as
glycogen to be used during times of fast. Our group previously
demonstrated [5] an increased non-oxidative glucose metabo-
lism and a clear relationship between increased HGP by the
liver and high post-prandial glucose levels in people with CF.
Thus, control of post-prandial glucose levels may be especially
relevant in CF patients, even before a diagnosis of CFRD. The
third purpose of our study was to evaluate the effectiveness of
the insulin pump on post-prandial hyperglycemia and on HGP.
Our study of six months of CSII therapy in CFRD was
designed to evaluate safety efficacy and metabolic benefits of
the pump in this patient population.
2. Research design and methods
2.1. Subject recruitment
Subjects ages 18–32 years with known CFRD were recruited
by direct invitation from the adult CF clinics at University of
Texas Southwestern and Baylor College of Medicine. CFRD
was diagnosed by National CF Foundation Consensus Con-
ference Guidelines [1] and all patients had fasting hyperglyce-
mia at the time of diagnosis. Inclusion criteria: 1) treated with
subcutaneous insulin injections by Endocrinologist DSH, a
minimum of 3 injections per day, for a minimum of six months;
2) subcutaneous insulin therapy based on a basal/bolus regimen;
3) recording of blood sugar readings a minimum of 4 times per
day; 4) demonstrating competency in carbohydrate quantifica-
tion; 5) judged to be compliant with both CF and diabetes
medications as ascertained by clinic staff. Exclusion criterion:
1) pregnancy; 2) use of an oral anti-DM drug; 3) infection with
Burkholderia cepacia or methicillin resistant staphylococcus
aureus; 4) non-adherence to therapy previously prescribed for
diabetes care.
These research protocols were approved by the Institutional
Review Boards at University of Texas Southwestern and Baylor
College of Medicine.2.2. Methods
2.2.1. Conversion to CSII therapy
Patients were converted to CSII therapy in a single visit
which was done in conjunction with the baseline stable isotope
studies. Once the stable isotope studies were completed, the
patient was started on CSII with the first bolus dose given with
lunch. The bolus doses were started in the same insulin to
carbohydrate ratio used in the previous two weeks. The initial
basal dose was calculated by subtracting 20% from the basal
dose given by subcutaneous injection. The remaining basal dose
was divided that 3/4 of the total was given in continuous
infusion calculated at an hourly rate from 8 AM to midnight and
the remaining 1/4 of the total was given from midnight to 8 AM.
Only two basal doses were initially set. The patient was
discharged by 3 PM the same day as CSII initiation.
Telephone contact was made with patient two to three times
per day for the three days following pump initiation and basal/
bolus doses were adjusted to maintain the first morning
glucoses 95–120 mg/dl, pre-meal 75–110 mg/dl and post-
prandial b150 mg/dl. Patients were asked to record blood sugar
levels in written logs and results were verified at study visits by
review of meter memory. Blood sugar levels were checked at 3
am for these three days and basal at night was lowered if the
3 AM was less than 100 mg/dl.
Patients were seen weekly for the first two weeks, then every
three months. Patients were instructed to monitor the blood
sugar pattern at least weekly and to contact us if more than 20%
of the readings were outside of the target range as described
above. We increased or decreased insulin as needed with each
patient contact.
Patient education for technical use of the insulin pump was
done during the three hour isotope infusion by a home pump
training nurse certified by Medtronics (Northridge, CA) and/or
Disetronic (Disetronic Medical Systems, Inc, Fishers, IN). Five
patients were treated with a Disetronic pump (D-Tron Plus) and
4 with a Medronic pump (paradigm 520).
2.2.2. Blood sugar monitoring
Subjects were asked to report results of self blood glucose
monitoring and to conduct pre-meal blood sugars before all
major meals, as well as before bed. We also asked that they
monitor a minimum of four post-meal blood glucose levels
measured two hours post lunch or supper each week. Subjects
were provided an Accucheck™ blood glucose meter (Roche
Diagnostics, Indianapolis Indiana) and test strips throughout the
study.
2.2.3. Body weight and lean body mass
Total Body Lean mass was measured by DXA (Lunar
Prodigy) at baseline and 6 months. Body weight was measured
by a standard scale in transplant in the General Clinical Research
Center (GCRC) at each study visit.
2.2.4. Stable isotope studies
Subjects were admitted to the GCRC the night before the
pump initiation. An IV catheter was inserted in the ante-cubital
Table 1
Subject characteristics at baseline and after 6 months of CSII therapy.
Weight LBM HbA1c FBG 2 h PP Insulin dose
(kg) (kg) (%) (mg/dl) (mg/dl) (U/kg/day)
Baseline 55.63±3.5 48.2±1.5 8.2±1.9 141±41 184±44 1.4±0.5
CSII 59.2±3.3 50.6±1.6 7.1±1.5 111±27 158±32 1.6±0.5
p=0.01 p=0.03 p=0.05 p=0.04 p=0.04 p=0.04
Note the significant increase in body weight and lean mass. The reduction of
pre-meal and post-meal blood sugar levels was significant. Although reduction
of HbA1c was not statistically significant, lower HbA1c is clinically significant
in documenting improved glycemic control. Interestingly, there was no
significant difference in total daily insulin dose per kilogram of body weight.
Fig. 1. This depicts whole body leucine rate of appearance, a measure of protein
catabolism. The studies were conducted using the stable isotope [1-13C]leucine.
As demonstrated, protein catabolism decreased following CSII.
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remained NPO except for water until 7 AM the morning of
stable isotope studies. Expired breath samples were collected in
an anesthesia bag every minute for 5 min, and was followed by
collection of two baseline breath samples. All breath samples
were transferred to specially prepared tubes for future analysis
of 13CO2. After collection of baseline breath samples, 20 cc's of
blood was withdrawn from the IV for baseline serum samples.
Following baseline we next began infusion of the stable isotope
[1-13C]NaHCO3 (bolus 0.2 mg/kg) and [1-
13C]leucine (bolus
0.35 mg/kg, followed by 0.65 mg/kg/h). We also gave a bolus
dose (2.5 mg/kg) of [6,6-2H2] glucose, followed by a
continuous infusion 2.0 mg/kg/h. These were infused for 3 h
(isotopic equilibration period) then blood was withdrawn in
triplicate for steady state samples. Whole body protein turnover
was measured at baseline and 6 months. Blood samples were
drawn at baseline and after the isotopic equilibration period.
Blood was separated and frozen for future analysis.
2.2.5. Hemoglobin A1C
Hemoglobin A1C was measured in each patient at baseline
and every three months to discern change in blood sugar control
resulting from pump therapy. Results were obtained from the
CLIA (Clinical Laboratory Improvement Amendments) accre-
dited laboratories at the General Clinical Research Center
(GCRC).
2.3. In vitro methods
2.3.1. Hepatic glucose production and protein turnover
The blood samples collected for analysis of HGP and protein
turnover were derivatized according to standard protocol and
measured by GC mass spectrophotometric measure. Leucine
rate of appearance and glucose rate of appearance were deter-
mined at steady state by the equation Ra= i(E1 /Ep−1) in which
i is the infusion rate of tracer in micromoles per kg/h; E1 is the
isotopic abundance of tracer, and Ep is the isotopic abundance
in plasma at isotopic plateau (each expressed as moles percent
excess). Calculations were made using a mean of three
measurements obtained during the last 15 min of each infusion
period. Protein breakdown was estimated from serum samples,
and protein synthesis was estimated from breath samples.
Leucine flux was calculated from the plasma leucine enrichment
(the secondary pool model) [21].2.4. Statistics
Each subject's values for all metabolic parameters were
compared to himself/herself at baseline, and six months. These
values were used to calculate a mean and standard deviation.
Significance was assigned to p value less than 0.05.
3. Results
We recruited 9 CF patients (5 males, 4 females, age 27±
4 years). All subjects approached agreed to participate in the
study. We quit recruiting after the first 9 subjects agreed to
participate as that was our target enrollment. Subject character-
istics at baseline are provided by Table 1. At the commencement
of the study, patients reported only “occasional” use of bolus
dosing for snacks, but acknowledged using correction for
hyperglycemia “most of the time.” Each patient utilized one
dose of LANTUS® (insulin glargine [rDNA origin] injection)
which according to the product insert lasts “up to 24 h” given in
the morning. LANTUS® represented 25–33% of the total daily
subcutaneous insulin dose. The rest of the daily insulin was
given with meals in the form of rapid-acting insulin boluses.
Although most patients took four insulin injections per day
(3 rapid-acting and one LANTUS®); two did not eat breakfast
and therefore only took a bolus of rapid-acting insulin with their
two main meals of the day.
At the end of the study, all patients, but one, wanted to
continue pump therapy. The patient who wished to discontinue
pump use stated that he “likes having lows (hypoglycemia) with
subcutaneous insulin because they make me eat more.” No
patient had an episode of hypoglycemia (defined as blood
glucose b70 mg/dl) during the study. However, prior to CSII,
patients reported having “several” hypoglycemic episodes per
month. The basal insulin dose represented 40–48% of the total
daily insulin dose delivered by CSII. Patients reported taking
bolus dose for snacks “most” or “all” of the time, and stated they
utilized correction for hyperglycemia “all of the time.” Blood
sugar levels improved both pre- and post-meal, as did HbA1c
(Table 1).
In addition to the improvement in glycemic control, there
were clear anabolic benefits. Body weight improved in all
subjects, as did lean mass (Table 1).
Fig. 2. This depicts endogenous (hepatic) glucose production, as measured by
the stable isotope 6,6-[2H2] glucose. Use of CSII resulted in lower hepatic
glucose production (HGP).
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decreased with CSII (Fig. 1) and HGP was lower (Fig. 2).
There were no technical problems reported with the pumps
during the study. We did not measure number of hospitalizations
or CF exacerbations as an end-point of this study.
4. Discussion
The 1998 CF Foundation Consensus Conference recognized
[1] four major categories of glucose tolerance in CF: 1) normal
glucose tolerance (FBGb126; ppb150); 2) impaired glucose
tolerance (FBGb126; pp 151–200); 3) diabetes w/o fasting
hyperglycemia (FBGb126; ppN200), a type of impaired
glucose tolerance and 4) diabetes with fasting hyperglycemia,
(FBGN126 and ppN200). Results of the conference mandated
that patients with CFRD with fasting hyperglycemia receive
insulin therapy, and no other type of therapy was recommended
[1]. Due to the significant need for caloric intake, most CF
patients eat many small meals per day [6]. People with CFRD
are no exception and require multiple injections to maintain
euglycemia [22]. Understandably, taking insulin is often
weighed against eating. Patients choosing to omit either the
meal or the injection do not receive enough nutrition. The
ability to give multiple bolus doses of insulin is an important
benefit of the insulin pump and results from this study clearly
demonstrate improved glycemic control.
It is interesting metabolic benefits were noted despite the fact
that insulin doses were similar with CSII and subcutaneous
insulin therapy. This is likely secondary to the closer approxi-
mation of physiologic insulin secretion. Patients acknowledged
greater use of correction dosing and utilized insulin bolus for
snacks in addition to meals. We hypothesize that regular use of
correction dosing and more frequent bolus (both meals and
snacks) resulted in decreased HGP thus contributing to lower
post-prandial blood sugar levels.
CFRD is associated with weight loss and with increased
morbidity [13,23]. One reason is that insulin is a major anabolic
hormone. People with insulin deficiency do not adequately store
fat and have excessive protein breakdown. Several studies in CF
have demonstrated improvement in body weight and lean body
mass after as little as one month of insulin therapy [24,25]. Our
study has demonstrated improvement in both body weight andlean mass when insulin is delivered by CSII, rather than by
multiple daily subcutaneous injection.
We have also demonstrated an additional benefit on protein
turnover using CSII. Multiple studies have demonstrated protein
catabolism in CF [15,26,27]. In the post-absorptive state, the rate
of appearance of leucine (leucine Ra) reflects the absolute
protein breakdown rate. Our group documented resistance to
insulin's anti-catabolic effect in the fasted state [16], and Moran
demonstrated [18] similar results in the fed state.
Prior to CSII, our subjects, all with fasting hyperglycemia,
had been treated with basal/bolus insulin; however they still
demonstrated decreased catabolism. CSII resulted in decreased
protein catabolism. This is likely secondary to our ability to give
continuous basal insulin at an ideal dose. In general, patients
with CFRD are treated with basal insulin injected subcuta-
neously only one time per day. As noted, generally the dose is
only 25–33% of the daily total, as higher dosing can cause
hypoglycemia. This dose is generally given in the morning
because the need for insulin is much lower at night if the patient
has normalized post-meal blood sugar levels and is not treated
with night-time enteral feedings. CSII provides a significant
advantage by allowing continued basal coverage throughout the
night without risk of hypoglycemia. Furthermore, the dose can
be divided over a 24 hour period and thus is high as 40–50% of
the daily total insulin dose. It appears that providing continuous
basal coverage, even at a low rate, provides an important benefit
on protein catabolism. This finding could be generalized to the
non-diabetic, yet insulin deficient, CF patient who might benefit
from a very low dose of basal insulin.
In conclusion, our study of CSII in patient with CFRD
demonstrated safety and improved glycemic control compared
to multiple daily subcutaneous insulin injections.
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